CPRO.JK
PT Central Proteina Prima Tbk
JakartaIDREQUITY
Consumer Defensive
DELAYED
Last price
50.00
■ 0.00 (0.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
50.00
Prev close
50.00
Day high
50.00
Day low
50.00
Volume
3.78M
Market cap
$2.98T
P/E (TTM)
9.26
52W range
50.00 – 88.00
Day trading desk
Gap from prior close
0.00%
Prior close 50.00
VWAP
50.00
0.00% from price
Relative volume
0.12×
Quiet session
Session range
—
50.00 – 50.00
Position in range
—
—
ATR (14D)
1.36
2.71% of price
Prior day high
50.00
PDH
Prior day low
50.00
PDL
Bid / ask spread
—
Quote not published
Session volume
7.37M
Avg 63.76M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-3.85%
-2.5%
1M
-1.96%
-5.7%
3M
-1.96%
-5.1%
6M
-24.24%
-35.3%
YTD
-20.63%
-32.9%
1Y
-1.96%
-22.0%
3Y
-5.66%
-79.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
16 more panels on CPRO.JK open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
27.03B
Total on file
Fundamentals
Market cap$2.98T
Enterprise value$4.47T
Revenue (TTM)$10.25T
Gross profit$1.96T
EBITDA$878.18B
Net income$322.82B
EPS (TTM)$5.40
Free cash flow$88.79B
Total cash$83.88B
Total debt$1.58T
Book value / share$66.82
Shares outstanding40.47B
Float13.44B
Short % of float—
Dividend yield—
Beta (5Y)-0.02
Valuation & profitability ratios
Trailing P/E9.26
Forward P/E—
PEG ratio—
Price / sales—
Price / book0.75
EV / revenue0.44
EV / EBITDA5.10
Gross margin19.09%
Operating margin7.72%
Profit margin3.15%
Return on equity8.24%
Return on assets6.87%
Debt / equity39.60
Current ratio1.19
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $9.95T | $9.28T | $9.03T | $8.24T | +7.2% |
| Operating revenue | $9.95T | $9.28T | $9.03T | $8.24T | +7.2% |
| Cost of revenue | $7.95T | $7.43T | $7.34T | $6.60T | +7.0% |
| Gross profit | $2.00T | $1.85T | $1.69T | $1.64T | +8.0% |
| Selling, general & admin | $584.37B | $471.44B | $415.95B | $387.22B | +24.0% |
| Total operating expense | $1.13T | $1.03T | $931.28B | $821.46B | +10.1% |
| Operating income | $863.80B | $819.28B | $756.13B | $823.25B | +5.4% |
| Net interest income | -$162.37B | -$197.07B | -$212.20B | -$240.34B | +17.6% |
| Pre-tax income | $627.06B | $448.99B | $522.56B | $476.68B | +39.7% |
| Tax provision | $202.99B | $128.83B | $120.79B | $102.70B | +57.6% |
| Net income | $423.65B | $319.98B | $401.47B | $373.67B | +32.4% |
| Net income to common | $423.65B | $319.98B | $401.47B | $373.67B | +32.4% |
| Basic EPS | 7.10 | 5.40 | 6.70 | 6.30 | +31.5% |
| Diluted EPS | 7.10 | 5.40 | 6.70 | 6.30 | +31.5% |
| EBIT | $776.81B | $632.53B | $720.64B | $695.13B | +22.8% |
| EBITDA | $834.72B | $692.40B | $779.36B | $750.34B | +20.6% |
| Basic shares | 59.57B | 59.57B | 59.57B | 59.57B | 0.0% |
| Diluted shares | 59.57B | 59.57B | 59.57B | 59.57B | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $135.48B | $99.31B | $74.87B | $77.89B | +36.4% |
| Cash & short-term investments | $135.48B | $99.31B | $74.87B | $77.89B | +36.4% |
| Accounts receivable | $992.46B | $861.87B | $776.57B | $628.94B | +15.2% |
| Inventory | $1.89T | $1.40T | $1.45T | $1.36T | +34.6% |
| Total current assets | $3.09T | $2.43T | $2.37T | $2.16T | +27.1% |
| Property, plant & equipment | $3.52T | $3.66T | $3.86T | $4.04T | -3.9% |
| Goodwill & intangibles | $9.35B | $8.07B | $12.74B | $15.50B | +15.9% |
| Total assets | $7.22T | $6.71T | $6.86T | $6.83T | +7.6% |
| Total current liabilities | $2.83T | $2.37T | $2.23T | $1.98T | +19.5% |
| Current debt | $1.57T | $1.41T | $1.37T | $1.10T | +11.8% |
| Long-term debt | $36.90B | $226.22B | $717.20B | $1.18T | -83.7% |
| Total debt | $1.69T | $1.72T | $2.15T | $2.34T | -1.7% |
| Total liabilities | $3.43T | $3.14T | $3.44T | $3.65T | +9.2% |
| Retained earnings | -$2.58T | -$3.00T | -$3.33T | -$3.75T | +14.0% |
| Shareholder equity | $3.79T | $3.57T | $3.42T | $3.18T | +6.2% |
| Working capital | $262.85B | $64.25B | $145.91B | $180.87B | +309.1% |
| Net tangible assets | $3.78T | $3.56T | $3.40T | $3.16T | +6.2% |
| Shares issued | 59.57B | 59.57B | 59.57B | 59.57B | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Capital expenditure | -$228.03B | -$203.75B | -$117.16B | -$165.56B | — | -11.9% |
| Investing cash flow | -$226.89B | -$203.41B | -$115.93B | -$164.41B | — | -11.5% |
| Dividends paid | -$300.00M | -$600.00M | — | — | -$670.00M | +50.0% |
| Financing cash flow | -$107.25B | -$538.58B | -$209.45B | -$148.08B | — | +80.1% |
| Free cash flow | $141.68B | $561.95B | $206.33B | $118.66B | — | -74.8% |
| End cash position | $135.48B | $99.31B | $74.87B | $77.89B | — | +36.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $2.59T | $2.47T | $2.61T | $2.36T | $2.40T | +4.9% |
| Operating revenue | $2.59T | $2.47T | $2.61T | $2.36T | $2.40T | +4.9% |
| Cost of revenue | $2.10T | $2.01T | $2.11T | $1.89T | $1.89T | +4.4% |
| Gross profit | $492.20B | $458.33B | $504.88B | $472.54B | $505.35B | +7.4% |
| Selling, general & admin | $148.76B | $165.47B | $162.45B | $125.13B | $139.35B | -10.1% |
| Total operating expense | $295.46B | $283.61B | $337.00B | $266.32B | $248.00B | +4.2% |
| Operating income | $196.74B | $174.72B | $167.88B | $206.22B | $257.35B | +12.6% |
| Net interest income | -$31.81B | -$31.46B | -$41.49B | -$42.85B | -$36.49B | -1.1% |
| Pre-tax income | $136.94B | $135.35B | $61.03B | $176.33B | $211.61B | +1.2% |
| Tax provision | $44.42B | $35.27B | $64.02B | $42.99B | $51.52B | +25.9% |
| Net income | $92.40B | $99.99B | -$3.08B | $133.25B | $159.97B | -7.6% |
| Net income to common | $92.40B | $99.99B | -$3.08B | $133.25B | $159.97B | -7.6% |
| Basic EPS | — | 1.70 | — | — | 2.70 | — |
| Diluted EPS | — | 1.70 | — | — | 2.70 | — |
| EBIT | $167.74B | $163.37B | $101.11B | $212.30B | $244.66B | +2.7% |
| EBITDA | $183.33B | $178.93B | $115.99B | $231.28B | $258.71B | +2.5% |
| Basic shares | — | 59.57B | — | — | 59.57B | — |
| Diluted shares | — | 59.57B | — | — | 59.57B | — |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $83.88B | $104.84B | $135.48B | $72.56B | $58.52B | -20.0% |
| Cash & short-term investments | $83.88B | $104.84B | $135.48B | $72.56B | $58.52B | -20.0% |
| Accounts receivable | $976.57B | $993.90B | $992.46B | $836.05B | $856.28B | -1.7% |
| Inventory | $1.82T | $1.71T | $1.89T | $1.51T | $1.44T | +7.0% |
| Total current assets | $3.03T | $2.93T | $3.09T | $2.52T | $2.46T | +3.3% |
| Property, plant & equipment | $3.55T | $3.53T | $3.52T | $3.72T | $3.72T | +0.3% |
| Goodwill & intangibles | $8.29B | $11.66B | $9.35B | $13.46B | $14.36B | -28.8% |
| Total assets | $7.20T | $7.09T | $7.22T | $6.84T | $6.81T | +1.6% |
| Total current liabilities | $2.55T | $2.60T | $2.83T | $2.35T | $2.35T | -1.7% |
| Current debt | $1.46T | $1.65T | $1.57T | $1.47T | $1.46T | -11.3% |
| Long-term debt | $15.68B | $26.81B | $36.90B | $140.09B | $178.40B | -41.5% |
| Total debt | $1.58T | $1.78T | $1.69T | $1.69T | $1.72T | -11.3% |
| Total liabilities | $3.22T | $3.19T | $3.43T | $2.98T | $3.08T | +0.6% |
| Retained earnings | -$2.39T | -$2.48T | -$2.58T | -$2.71T | -$2.84T | +3.7% |
| Shareholder equity | $3.98T | $3.89T | $3.79T | $3.86T | $3.73T | +2.4% |
| Working capital | $477.13B | $334.93B | $262.85B | $175.06B | $113.88B | +42.5% |
| Net tangible assets | $3.97T | $3.88T | $3.78T | $3.85T | $3.71T | +2.5% |
| Shares issued | 59.57B | 59.57B | 59.57B | 59.57B | 59.57B | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Capital expenditure | -$43.64B | -$24.18B | -$53.14B | -$31.13B | -$88.07B | -80.5% |
| Investing cash flow | -$43.56B | -$24.18B | -$53.14B | -$31.13B | -$88.06B | -80.1% |
| Financing cash flow | -$150.33B | $49.84B | -$21.09B | -$85.52B | -$13.43B | -401.7% |
| Free cash flow | $128.75B | -$80.57B | $73.34B | $99.92B | -$27.82B | +259.8% |
| End cash position | $83.88B | $104.84B | $135.48B | $72.56B | $58.52B | -20.0% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders45.37%
Held by institutions0.09%
Institutions holding2
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
51.00
-1.96% from price
SMA 20
50.70
-1.38% from price
SMA 50
50.40
-0.79% from price
SMA 100
52.50
-4.76% from price
SMA 200
58.18
-14.05% from price
EMA 12
50.62
-1.23% from price
EMA 26
50.66
-1.31% from price
EMA 50
51.06
-2.07% from price
RSI (14)
44.8
Neutral
MACD (12,26,9)
-0.04
Hist -0.14
ATR (14)
1.36
2.71% of price
Realised vol 30D
25.4%
Annualised
Bollinger upper
52.39
20, 2σ
Bollinger lower
49.01
20, 2σ
50 / 200 cross
Death
50.40 vs 58.18
Trend bias
Below 200
-14.05%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.14
Less volatile than market
Correlation to SPY
0.03
Largely independent
Realised vol 30D
25.4%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-41.9%
Peak to trough
Max drawdown 5Y
-60.3%
Peak to trough
ATR 14
1.36
2.71% of price
Beta (reported)
-0.02
5Y monthly, from filing
Headlines
3 Unpopular Stocks We Steer Clear Of
StockStory · 9m ago
Oleria and Happiest Minds Partner to Accelerate Modern Identity Governance for AI-First Enterprises
ACCESS Newswire · 11m ago
Vicore Pharma to Present at the European Respiratory Society Congress 2026
ACCESS Newswire · 11m ago
Dollar trading near multi-month lows, restrained by debt nerves
Reuters · 12m ago
Billionaire Investor Stanley Druckenmiller Sold Broadcom, Intel, and Micron and Bought Another Chip Stock That Expects to Double Data Center Sales in 2027
Motley Fool · 21m ago
TME Pharma provides update on its activities
GlobeNewswire · 21m ago
American Chemical Society Names Syngenta's Camilla Corsi the 2026 Winner of Prestigious International Award for Research in Agrochemicals
Business Wire · 26m ago
Valerio Therapeutics Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and €40.25 Million PIPE Financing From New and Existing Investors
Business Wire · 26m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.